Luo ChangLiang, Lin Zhongyuan, Huang Fangfang, Ning Leping, Yuan Yulin
Department of Clinical Laboratory, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People's Republic of China.
Cancer Manag Res. 2025 Jan 3;17:1-9. doi: 10.2147/CMAR.S498516. eCollection 2025.
(Tumor-educated platelets) TEPs have emerged as active players in all steps of tumorigenesis, confrontation of platelets with tumor cells via transfer of tumor-associated biomolecules and results in the sequestration of such biomolecules. The current study was aimed to examine whether TEPs lncRNA-STARD4-AS1 and ELOA-AS1 might be potential biomarkers for NSCLC.
TEPs were obtained by low-speed centrifugation. Quantitative real-time PCR was used to determine the expression level of TEPs-STARD4-AS1, ELOA-AS1 in the training cohort and the validation cohort. ROC curve was generated to evaluate their diagnostic value. Correlations between TEPs-STARD4-AS1, ELOA-AS1 and clinical parameters were further analyzed.
Our results showed that the level of TEPs-STARD4-AS1 and ELOA-AS1 significantly upregulated in patients with NSCLC compared with healthy controls in the two cohorts. By ROC analysis, we found that TEPs-STARD4-AS1, ELOA-AS1 could offer valuable diagnostic performance for NSCLC patients (AUC = 0.800/0.774, and AUC = 0.754/0.718 for diagnosing adenocarcinoma and squamous cell carcinoma cases from controls, respectively). The combination of TEP-STARD4-AS1 and ELOA-AS1 improved the diagnostic efficiency of NSCLC. Clinicopathological analysis further revealed that TEPs-STARD4-AS1 level significantly correlated with tumor-node-metastasis (TNM) stage (p = 0.011), while TEPs-ELOA-AS1 expression significantly correlated with tumor-node-metastasis (TNM) stage and (p = 0.019) distant metastasis (p = 0.004).
Our data suggested that TEPs-STARD4-AS1 and ELOA-AS1 are promising non-invasive circulating diagnostic markers for NSCLC.
肿瘤诱导血小板（TEPs）已成为肿瘤发生各个阶段的活跃参与者，血小板通过转移肿瘤相关生物分子与肿瘤细胞相互作用，并导致此类生物分子的隔离。本研究旨在探讨TEPs的lncRNA-STARD4-AS1和ELOA-AS1是否可能是NSCLC的潜在生物标志物。
通过低速离心获得TEPs。采用定量实时PCR法测定训练队列和验证队列中TEPs-STARD4-AS1、ELOA-AS1的表达水平。绘制ROC曲线以评估其诊断价值。进一步分析TEPs-STARD4-AS1、ELOA-AS1与临床参数之间的相关性。
我们的结果显示，与两个队列中的健康对照相比，NSCLC患者中TEPs-STARD4-AS1和ELOA-AS1的水平显著上调。通过ROC分析，我们发现TEPs-STARD4-AS1、ELOA-AS1可为NSCLC患者提供有价值的诊断性能（AUC = 0.800/0.774，分别用于从对照中诊断腺癌和鳞状细胞癌病例时的AUC = 0.754/0.718）。TEP-STARD4-AS1和ELOA-AS1的组合提高了NSCLC的诊断效率。临床病理分析进一步显示，TEPs-STARD4-AS1水平与肿瘤-淋巴结-转移（TNM）分期显著相关（p = 0.011），而TEPs-ELOA-AS1表达与肿瘤-淋巴结-转移（TNM）分期（p = 0.019）和远处转移（p = 0.004）显著相关。
我们的数据表明，TEPs-STARD4-AS1和ELOA-AS1是有前景的NSCLC非侵入性循环诊断标志物。
